Emergent Advances and Subgroup Data in ER+, HER2- Metastatic Breast Cancer from SABCS 2023

A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.

A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.

Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.

Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.

Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.

Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.

Dr. Paolo Tarantino discusses the current treatment landscape of ER+/HER2- low metastatic breast cancer and unmet needs.

A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.

Dr. Paolo Tarantino offers expert guidance on optimizing outcomes for patients with ER+/HER2-low metastatic breast cancer.